Prediction of preeclampsia in asymptomatic women
Issued Date
2024-02-01
Resource Type
ISSN
15216934
eISSN
15321932
Scopus ID
2-s2.0-85179062709
Pubmed ID
38056380
Journal Title
Best Practice and Research: Clinical Obstetrics and Gynaecology
Volume
92
Rights Holder(s)
SCOPUS
Bibliographic Citation
Best Practice and Research: Clinical Obstetrics and Gynaecology Vol.92 (2024)
Suggested Citation
Lee N.M.W., Chaemsaithong P., Poon L.C. Prediction of preeclampsia in asymptomatic women. Best Practice and Research: Clinical Obstetrics and Gynaecology Vol.92 (2024). doi:10.1016/j.bpobgyn.2023.102436 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/91508
Title
Prediction of preeclampsia in asymptomatic women
Author(s)
Other Contributor(s)
Abstract
Preeclampsia is a major cause of maternal and perinatal morbidity and mortality. It is important to identify women who are at high risk of developing this disorder in their first trimester of pregnancy to allow timely therapeutic intervention. The use of low-dose aspirin initiated before 16 weeks of gestation can significantly reduce the rate of preterm preeclampsia by 62 %. Effective screening recommended by the Fetal Medicine Foundation (FMF) consists of a combination of maternal risk factors, mean arterial pressure, uterine artery pulsatility index (UtA-PI) and placental growth factor (PLGF). The current model has detection rates of 90 %, 75 %, and 41 % for early, preterm, and term preeclampsia, respectively at 10 % false-positive rate. Similar risk assessment can be performed during the second trimester in all pregnant women irrespective of first trimester screening results. The use of PLGF, UtA-PI, sFlt-1 combined with other investigative tools are part of risk assessment.